US20110160261A9 - Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents - Google Patents

Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents

Info

Publication number
US20110160261A9
US20110160261A9 US12205303A US20530308A US2011160261A9 US 20110160261 A9 US20110160261 A9 US 20110160261A9 US 12205303 A US12205303 A US 12205303A US 20530308 A US20530308 A US 20530308A US 2011160261 A9 US2011160261 A9 US 2011160261A9
Authority
US
United States
Prior art keywords
methods
dantrolene
provides
therapeutic agents
improved delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12205303A
Inventor
Ahmad Malkawi
Abeer Al-Ghananeem
Patrick Deluca
George Digenis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Us Worldmeds Holdings LLC
Us Worldmeds Ventures LLC
Uswm Enterprises LLC
Uswm LLC
Original Assignee
US WORLDMEDS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US WORLDMEDS LLC filed Critical US WORLDMEDS LLC
Priority to US12/205,303 priority Critical patent/US8975284B2/en
Publication of US20090093531A1 publication Critical patent/US20090093531A1/en
Assigned to US WORLDMEDS LLC reassignment US WORLDMEDS LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DIGENIS, GEORGE A., AL-GHANANEEM, ABEER M., DELUCA, PATRICK, MALKAWI, AHMAD
Publication of US20110015243A2 publication Critical patent/US20110015243A2/en
Publication of US20110160261A2 publication Critical patent/US20110160261A2/en
Publication of US20110160261A9 publication Critical patent/US20110160261A9/en
Assigned to JPMORGAN CHASE BANK, N.A. reassignment JPMORGAN CHASE BANK, N.A. SECURITY AGREEMENT Assignors: US WORLDMEDS, LLC
Publication of US8975284B2 publication Critical patent/US8975284B2/en
Application granted granted Critical
Assigned to US WORLDMEDS, LLC reassignment US WORLDMEDS, LLC NOTICE OF RELEASE OF SECURITY INTEREST (RECORDED 9/25/12 AT REEL/FRAME 029033/0301) Assignors: JPMORGAN CHASE BANK, N.A.
Assigned to ATHYRIUM OPPORTUNITIES II ACQUISITION LP, AS ADMINISTRATIVE AGENT reassignment ATHYRIUM OPPORTUNITIES II ACQUISITION LP, AS ADMINISTRATIVE AGENT NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Assignors: US WORLDMEDS, LLC
Assigned to PNC BANK, NATIONAL ASSOCIATION reassignment PNC BANK, NATIONAL ASSOCIATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOLSTICE NEUROSCIENCES, LLC, US WORLDMEDS HOLDINGS, LLC, US WORLDMEDS, LLC, USWM ENTERPRISES, LLC, USWM HQ, LLC, USWM LICENSE COMPANY, LLC, USWM SPE, LLC
Assigned to CRG SERVICING LLC, AS ADMINISTRATIVE AGENT reassignment CRG SERVICING LLC, AS ADMINISTRATIVE AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: US WORLDMEDS, LLC
Assigned to US WORLDMEDS, LLC reassignment US WORLDMEDS, LLC RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: ATHYRIUM OPPORTUNITIES II ACQUISITION LP, AS ADMINISTRATIVE AGENT
Assigned to US WORLDMEDS HOLDINGS, LLC reassignment US WORLDMEDS HOLDINGS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: US WORLDMEDS, LLC
Assigned to USWM HQ, LLC, USWM SPE, LLC, USWM LICENSE COMPANY, LLC, USWM ENTERPRISES, LLC, SOLSTICE NEUROSCIENCES, LLC, US WORLDMEDS HOLDINGS, LLC, US WORLDMEDS, LLC reassignment USWM HQ, LLC TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 037191/FRAME 0935 Assignors: PNC BANK, NATIONAL ASSOCIATION
Assigned to US WORLDMEDS, LLC reassignment US WORLDMEDS, LLC RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 039169/FRAME 0385 Assignors: CRG SERVICING LLC
Assigned to USWM ENTERPRISES, LLC reassignment USWM ENTERPRISES, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: US WORLDMEDS HOLDINGS, LLC
Assigned to USWM, LLC reassignment USWM, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: US WORLDMEDS VENTURES, LLC
Assigned to US WORLDMEDS VENTURES, LLC reassignment US WORLDMEDS VENTURES, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: USWM ENTERPRISES, LLC
Assigned to US WORLDMEDS HOLDINGS, LLC reassignment US WORLDMEDS HOLDINGS, LLC CORRECTIVE ASSIGNMENT TO CORRECT THE LANGUAGE IN SECTION 1 OF THE AGREEMENT PREVIOUSLY RECORDED ON REEL 052884 FRAME 0650. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: US WORLDMEDS, LLC
Assigned to USWM ENTERPRISES, LLC reassignment USWM ENTERPRISES, LLC CORRECTIVE ASSIGNMENT TO CORRECT THE LANGUAGE IN SECTION 1 OF THE AGREEMENT PREVIOUSLY RECORDED ON REEL 052884 FRAME 0707. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: US WORLDMEDS HOLDINGS, LLC
Assigned to US WORLDMEDS VENTURES, LLC reassignment US WORLDMEDS VENTURES, LLC CORRECTIVE ASSIGNMENT TO CORRECT THE LANGUAGE IN SECTION 1 OF THE AGREEMENT PREVIOUSLY RECORDED ON REEL 052884 FRAME 0819. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: USWM ENTERPRISES, LLC
Assigned to USWM, LLC reassignment USWM, LLC CORRECTIVE ASSIGNMENT TO CORRECT THE LANGUAGE IN SECTION 1 OF THE AGREEMENT PREVIOUSLY RECORDED ON REEL 052884 FRAME 0858. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: US WORLDMEDS VENTURES, LLC
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
US12/205,303 2007-10-09 2008-09-05 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents Active 2031-09-23 US8975284B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/205,303 US8975284B2 (en) 2007-10-09 2008-09-05 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97862607P 2007-10-09 2007-10-09
US12/205,303 US8975284B2 (en) 2007-10-09 2008-09-05 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents

Publications (5)

Publication Number Publication Date
US20090093531A1 US20090093531A1 (en) 2009-04-09
US20110015243A2 US20110015243A2 (en) 2011-01-20
US20110160261A9 true US20110160261A9 (en) 2011-06-30
US20110160261A2 US20110160261A2 (en) 2011-06-30
US8975284B2 US8975284B2 (en) 2015-03-10

Family

ID=40316940

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/205,303 Active 2031-09-23 US8975284B2 (en) 2007-10-09 2008-09-05 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents

Country Status (6)

Country Link
US (1) US8975284B2 (en)
EP (2) EP2219605B1 (en)
JP (1) JP5406197B2 (en)
CA (1) CA2702243C (en)
ES (1) ES2583804T3 (en)
WO (1) WO2009048698A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140072525A1 (en) * 2012-09-07 2014-03-13 Gaab, Llc Antimicrobial preparation and methods for making and using the same

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2069699A2 (en) * 2006-10-03 2009-06-17 Wyeth Lyophilization methods and apparatuses
WO2009067175A2 (en) * 2007-11-16 2009-05-28 Nektar Therapeutics Al, Corporation Oligomer-dantrolene conjugates and related compounds
US20120040970A1 (en) * 2009-04-27 2012-02-16 Al-Ghananeem Abeer M Intranasal delivery system for dantrolene
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
CN105209030B (en) * 2013-03-15 2018-06-12 罗莎琳德富兰克林医科大学 For stablizing the compound that blue Buddhist nun's alkali receptor makes it from the calcium release of abnormal level
WO2015157212A1 (en) * 2014-04-10 2015-10-15 Us Worldmeds, Llc Stable apomorphine composition and uses thereof
EP3364947B1 (en) * 2015-10-20 2021-09-15 B. Braun Melsungen AG Aqueous composition comprising dantrolene
CN110785165A (en) * 2017-06-20 2020-02-11 塔弗达治疗有限公司 Targeted therapeutic agents
KR102652642B1 (en) * 2017-10-20 2024-04-01 이글 리서치 랩스 리미티드 Dantrolene prodrug and method of use thereof
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
CN112040927A (en) * 2018-04-05 2020-12-04 塔弗达治疗有限公司 Pharmaceutical compositions with reduced levels of tertiary butanol
KR20210056359A (en) * 2018-09-06 2021-05-18 시믹 홀딩스 씨오., 엘티디. Dantrolene aqueous preparation and preparation method thereof
WO2022169582A1 (en) * 2021-02-05 2022-08-11 Uswm, Llc Compositions and methods for clear concentrated parenteral delivery of dantrolene therapeutic agents

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415821A (en) * 1965-09-07 1968-12-10 Norwich Pharma Co 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones
US4543359A (en) * 1982-10-01 1985-09-24 Eaton Laboratories, Inc. Treating cardiac arrhythmias with dantrolene sodium
US5122110A (en) * 1987-08-21 1992-06-16 Cryolife, Inc. Device and method for cryopreserving blood vessels
US5149621A (en) * 1987-08-21 1992-09-22 Cryolife, Inc. & Medical Univ. Of South Carolina Kit for cryopreserving blood vessels
US5158867A (en) * 1987-08-21 1992-10-27 Cryolife Inc. Method for cryopreserving blood vessels
JPH06263636A (en) * 1993-03-12 1994-09-20 Kiyoshi Kataoka Therapeutic agent for cerebral or higher nervous disease
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US20040242646A1 (en) * 2001-06-23 2004-12-02 Anderson David M. Treatment using dantrolene
US20060159713A1 (en) * 2005-01-14 2006-07-20 Cephalon, Inc. Bendamustine pharmaceutical compositions
US20070116729A1 (en) * 2005-11-18 2007-05-24 Palepu Nageswara R Lyophilization process and products obtained thereby
US8445524B2 (en) * 2008-03-26 2013-05-21 Cephalon, Inc. Solid forms of bendamustine hydrochloride

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01128923A (en) * 1987-11-11 1989-05-22 Mikasa Seiyaku Kk Skeletal muscle relaxing external preparation
AU5015193A (en) * 1992-09-09 1994-03-29 Washington University Prevention or treatment of sepsis with dantrolene or azumolene
AU2266995A (en) * 1994-04-21 1995-11-16 Hisamitsu Pharmaceutical Co., Inc. Percutaneously administrable base composition and percutaneously administrable drug composition prepared therefrom
EP1435781A4 (en) * 2001-06-23 2007-06-20 Lyotropic Therapeutics Llc Solvent system
EP1603513B1 (en) * 2003-03-04 2020-12-30 Lyotropic Therapeutics, Inc. Dantrolene compositions

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415821A (en) * 1965-09-07 1968-12-10 Norwich Pharma Co 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones
US4543359A (en) * 1982-10-01 1985-09-24 Eaton Laboratories, Inc. Treating cardiac arrhythmias with dantrolene sodium
US5122110A (en) * 1987-08-21 1992-06-16 Cryolife, Inc. Device and method for cryopreserving blood vessels
US5145769A (en) * 1987-08-21 1992-09-08 Cryolife Inc. Method for cryopreserving blood vessels
US5149621A (en) * 1987-08-21 1992-09-22 Cryolife, Inc. & Medical Univ. Of South Carolina Kit for cryopreserving blood vessels
US5158867A (en) * 1987-08-21 1992-10-27 Cryolife Inc. Method for cryopreserving blood vessels
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
JPH06263636A (en) * 1993-03-12 1994-09-20 Kiyoshi Kataoka Therapeutic agent for cerebral or higher nervous disease
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US20040242646A1 (en) * 2001-06-23 2004-12-02 Anderson David M. Treatment using dantrolene
US20060159713A1 (en) * 2005-01-14 2006-07-20 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US20130131131A1 (en) * 2005-01-14 2013-05-23 Jason Edward BRITTAIN Bendamustine Pharmaceutical Compositions
US8461350B2 (en) * 2005-01-14 2013-06-11 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8609863B2 (en) * 2005-01-14 2013-12-17 Cephalon, Inc. Bendamustine pharmaceutical compositions
US20140148490A1 (en) * 2005-01-14 2014-05-29 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8791270B2 (en) * 2005-01-14 2014-07-29 Cephalon, Inc. Bendamustine pharmaceutical compositions
US20070116729A1 (en) * 2005-11-18 2007-05-24 Palepu Nageswara R Lyophilization process and products obtained thereby
US8445524B2 (en) * 2008-03-26 2013-05-21 Cephalon, Inc. Solid forms of bendamustine hydrochloride
US8669279B2 (en) * 2008-03-26 2014-03-11 Cephalon, Inc. Solid forms of bendamustine hydrochloride
US20140187598A1 (en) * 2008-03-26 2014-07-03 Cephalon, Inc. Novel Solid Forms Of Bendamustine Hydrochloride

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kiyoshi (English translation of JP H06263636 A, cited by Applicant in the IDS filed 04/09/2009). *
Teagarden and Baker, Practical aspects of lyophilization using non-aqueous co-colvent systems, 2002, European Journal of Pharmaceutical Sciences, 15, pp. 115-133 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140072525A1 (en) * 2012-09-07 2014-03-13 Gaab, Llc Antimicrobial preparation and methods for making and using the same

Also Published As

Publication number Publication date
CA2702243A1 (en) 2009-04-16
ES2583804T3 (en) 2016-09-22
WO2009048698A4 (en) 2013-05-30
WO2009048698A9 (en) 2009-11-19
US20110015243A2 (en) 2011-01-20
EP2219605B1 (en) 2015-08-19
JP5406197B2 (en) 2014-02-05
CA2702243C (en) 2016-06-21
EP2583670A1 (en) 2013-04-24
EP2219605A1 (en) 2010-08-25
US8975284B2 (en) 2015-03-10
US20090093531A1 (en) 2009-04-09
JP2011500570A (en) 2011-01-06
WO2009048698A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
US20110160261A9 (en) Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
MX2022015695A (en) Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof.
UA99141C2 (en) Substituted indazole derivatives active as kinase inhibitors
AR058620A1 (en) PHARMACEUTICAL FORMULATION FOR THE SUPPLY OF INHIBITING COMPOUNDS OF THE THYROSINE KINASE RECEPTOR (RTKI) TO THE EYE
MX2009011898A (en) Compositions and methods for treating disorders associated with salt or fluid retention.
MX2009006401A (en) Indazole derivatives as kinase inhibitors for the treatment of cancer.
MX2019012657A (en) Inhibitors of bruton's tyrosine kinase.
MX2021004546A (en) Implantable drug delivery compositions and methods of use thereof.
EA201100971A1 (en) DERIVATIVES OF PYRIMIDININDOL FOR THE TREATMENT OF MALIGNANT NORMALIZATION
DOP2004000907A (en) PHARMACEUTICAL PROCEDURES AND COMPOSITIONS TO TREAT ATEROSCLEROSIS DISLIPIDEMIAS AND RELATED AFFECTIONS
NZ700182A (en) Parenteral formulations for administering macrolide antibiotics
MY181013A (en) Polymer conjugate for delivery of a bioactive agent
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
PH12021550537A1 (en) Oral formulations of kappa opioid receptor agonists
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
JO3122B1 (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments
PH12015500062A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
EP2358395A4 (en) Method and formulation for reducing aggregation of a macromolecule under physiological conditions
MX2013012206A (en) Method of producing substances with supersaturated gas, transdermal delivery thereof, and uses thereof.
JOP20200015A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
WO2008051527A3 (en) Sustained release of agents for localized pain management
MX2023005371A (en) Ρî¡î`rî³ modulators and methods of use.
MX369520B (en) Method for treating gynecological diseases.
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: US WORLDMEDS LLC, KENTUCKY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MALKAWI, AHMAD;AL-GHANANEEM, ABEER M.;DELUCA, PATRICK;AND OTHERS;REEL/FRAME:023211/0647;SIGNING DATES FROM 20080918 TO 20080922

Owner name: US WORLDMEDS LLC, KENTUCKY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MALKAWI, AHMAD;AL-GHANANEEM, ABEER M.;DELUCA, PATRICK;AND OTHERS;SIGNING DATES FROM 20080918 TO 20080922;REEL/FRAME:023211/0647

AS Assignment

Owner name: JPMORGAN CHASE BANK, N.A., OHIO

Free format text: SECURITY AGREEMENT;ASSIGNOR:US WORLDMEDS, LLC;REEL/FRAME:029033/0301

Effective date: 20120920

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: ATHYRIUM OPPORTUNITIES II ACQUISITION LP, AS ADMIN

Free format text: NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS;ASSIGNOR:US WORLDMEDS, LLC;REEL/FRAME:037166/0656

Effective date: 20151125

Owner name: US WORLDMEDS, LLC, KENTUCKY

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST (RECORDED 9/25/12 AT REEL/FRAME 029033/0301);ASSIGNOR:JPMORGAN CHASE BANK, N.A.;REEL/FRAME:037171/0805

Effective date: 20151125

AS Assignment

Owner name: PNC BANK, NATIONAL ASSOCIATION, PENNSYLVANIA

Free format text: SECURITY INTEREST;ASSIGNORS:US WORLDMEDS, LLC;SOLSTICE NEUROSCIENCES, LLC;USWM ENTERPRISES, LLC;AND OTHERS;REEL/FRAME:037191/0935

Effective date: 20151125

AS Assignment

Owner name: US WORLDMEDS, LLC, KENTUCKY

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:ATHYRIUM OPPORTUNITIES II ACQUISITION LP, AS ADMINISTRATIVE AGENT;REEL/FRAME:039169/0844

Effective date: 20160715

Owner name: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT, TEXAS

Free format text: SECURITY INTEREST;ASSIGNOR:US WORLDMEDS, LLC;REEL/FRAME:039169/0385

Effective date: 20160715

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4

AS Assignment

Owner name: USWM ENTERPRISES, LLC, KENTUCKY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:US WORLDMEDS HOLDINGS, LLC;REEL/FRAME:052884/0707

Effective date: 20200608

Owner name: US WORLDMEDS HOLDINGS, LLC, KENTUCKY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:US WORLDMEDS, LLC;REEL/FRAME:052884/0650

Effective date: 20200608

Owner name: USWM, LLC, KENTUCKY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:US WORLDMEDS VENTURES, LLC;REEL/FRAME:052884/0858

Effective date: 20200608

Owner name: US WORLDMEDS VENTURES, LLC, KENTUCKY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:USWM ENTERPRISES, LLC;REEL/FRAME:052884/0819

Effective date: 20200608

Owner name: USWM LICENSE COMPANY, LLC, KENTUCKY

Free format text: TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 037191/FRAME 0935;ASSIGNOR:PNC BANK, NATIONAL ASSOCIATION;REEL/FRAME:052888/0716

Effective date: 20200609

Owner name: USWM HQ, LLC, KENTUCKY

Free format text: TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 037191/FRAME 0935;ASSIGNOR:PNC BANK, NATIONAL ASSOCIATION;REEL/FRAME:052888/0716

Effective date: 20200609

Owner name: SOLSTICE NEUROSCIENCES, LLC, KENTUCKY

Free format text: TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 037191/FRAME 0935;ASSIGNOR:PNC BANK, NATIONAL ASSOCIATION;REEL/FRAME:052888/0716

Effective date: 20200609

Owner name: US WORLDMEDS HOLDINGS, LLC, KENTUCKY

Free format text: TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 037191/FRAME 0935;ASSIGNOR:PNC BANK, NATIONAL ASSOCIATION;REEL/FRAME:052888/0716

Effective date: 20200609

Owner name: USWM SPE, LLC, KENTUCKY

Free format text: TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 037191/FRAME 0935;ASSIGNOR:PNC BANK, NATIONAL ASSOCIATION;REEL/FRAME:052888/0716

Effective date: 20200609

Owner name: US WORLDMEDS, LLC, KENTUCKY

Free format text: RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 039169/FRAME 0385;ASSIGNOR:CRG SERVICING LLC;REEL/FRAME:052888/0907

Effective date: 20200609

Owner name: USWM ENTERPRISES, LLC, KENTUCKY

Free format text: TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 037191/FRAME 0935;ASSIGNOR:PNC BANK, NATIONAL ASSOCIATION;REEL/FRAME:052888/0716

Effective date: 20200609

Owner name: US WORLDMEDS, LLC, KENTUCKY

Free format text: TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 037191/FRAME 0935;ASSIGNOR:PNC BANK, NATIONAL ASSOCIATION;REEL/FRAME:052888/0716

Effective date: 20200609

AS Assignment

Owner name: US WORLDMEDS VENTURES, LLC, KENTUCKY

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE LANGUAGE IN SECTION 1 OF THE AGREEMENT PREVIOUSLY RECORDED ON REEL 052884 FRAME 0819. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:USWM ENTERPRISES, LLC;REEL/FRAME:054074/0245

Effective date: 20200608

Owner name: USWM ENTERPRISES, LLC, KENTUCKY

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE LANGUAGE IN SECTION 1 OF THE AGREEMENT PREVIOUSLY RECORDED ON REEL 052884 FRAME 0707. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:US WORLDMEDS HOLDINGS, LLC;REEL/FRAME:054074/0333

Effective date: 20200608

Owner name: USWM, LLC, KENTUCKY

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE LANGUAGE IN SECTION 1 OF THE AGREEMENT PREVIOUSLY RECORDED ON REEL 052884 FRAME 0858. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:US WORLDMEDS VENTURES, LLC;REEL/FRAME:054074/0197

Effective date: 20200608

Owner name: US WORLDMEDS HOLDINGS, LLC, KENTUCKY

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE LANGUAGE IN SECTION 1 OF THE AGREEMENT PREVIOUSLY RECORDED ON REEL 052884 FRAME 0650. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:US WORLDMEDS, LLC;REEL/FRAME:054074/0423

Effective date: 20200608

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8